Yes, genetic polymorphisms can influence CYP3A4 activity. These variations can lead to differences in drug metabolism rates among individuals, affecting the efficacy and safety of hormone-based therapies. Genetic testing may help tailor treatments to individual metabolic profiles, improving outcomes in gynecological care.
